Redeye comments on Physitrack’s soild Q1 figures, which were in line with our expectations. Highlights include quarter-on-quarter growth, an annual recurring revenue (ARR) increase of 15% y/y, positive FCF, and Software as a Service (SaaS) revenues now constituting 80% (71%) of total revenues. Consequently, we anticipate moderate adjustments to our near-term estimates and fair value range.